Advertisement

Frontiers of Medicine

, Volume 11, Issue 2, pp 191–202 | Cite as

Effect of traditional Chinese medicine combined with Western therapy on primary hepatic carcinoma: a systematic review with meta-analysis

  • Li Ma
  • Bin Wang
  • Yuanxiong Long
  • Hanmin Li
Review

Abstract

Primary hepatic carcinoma (PHC) is a common malignant tumor in China. Cancer is comprehensively treated with various therapeutic regimes, including traditional Chinese medicine (TCM). TCM has been widely used to improve the quality of life, delay the time of cancer progression, and prolong the median survival time. This systematic review with meta-analysis aimed to assess the effect of TCM combined with Western therapy on primary hepatic carcinoma. A comprehensive literature search was conducted in six databases, including CNKI, VIP, Wan-Fang Database, CBM, PubMed, and Cochrane library. A total of 44 randomized controlled trials (RCTs) involving 3429 participants suffering from PHC were selected. Meta-analysis results indicated that the overall effect of TCM and Western integrative treatment on PHC was higher than that of Western intervention alone, which can postpone tumor recurrence and metastasis and prolong the overall survival time of patients with PHC. Although the obtained evidence remained weak because of the poor methodological quality of the included studies, this review provided relevant data supporting the efficacy and safety of TCM combined with Western therapies. In future research, individual RCT studies should incorporate accepted standards for trial design and reporting, proper outcome indicators according to international standards, blinding in allocation concealment, and valid follow-up periods.

Keywords

traditional Chinese medicine primary hepatic carcinoma meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

This study is supported by the National Natural Science Foundation of China (Nos. 81373513 and 81274147), Research Projects of Key Disease of National Traditional Chinese Medicine (Hepatopathy) Clinical Research Center (Hubei Province) (No. JDZX2012054), Specialized Research Fund for the Doctoral Programs in Institution of Higher Education (No. 20124230110001), Key Subjects of Department of Science & Technology of Wuhan City (No. 201260523199), and Key Projects of Hubei Provincial Department of Education (No. D20152003).

Supplementary material

11684_2017_512_MOESM1_ESM.pdf (204 kb)
Supplementary material, approximately 204 KB.
11684_2017_512_MOESM2_ESM.pdf (294 kb)
Supplementary material, approximately 293 KB.
11684_2017_512_MOESM3_ESM.pdf (76 kb)
Supplementary material, approximately 76.3 KB.
11684_2017_512_MOESM4_ESM.xlsx (159 kb)
Supplementary material, approximately 159 KB.

References

  1. 1.
    Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012; 62(6): 394–399CrossRefPubMedGoogle Scholar
  2. 2.
    Wang WQ. Integrative treatment of primary hepatic carcinoma. China Pract Med (Zhongguo Shi Yong Yi Yao) 2010;(23):182 (in Chinese)Google Scholar
  3. 3.
    Zhu K, Dai Z, Pan Q, Wang Z, Yang GH, Yu L, Ding ZB, Shi GM, Ke AW, Yang XR, Tao ZH, Zhao YM, Qin Y, Zeng HY, Tang ZY, Fan J, Zhou J. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2011; 17(23): 7294–7302CrossRefPubMedGoogle Scholar
  4. 4.
    Parikh P, Malhotra H, Jelic S; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2): ii27–ii28CrossRefPubMedGoogle Scholar
  5. 5.
    Wang ZD, Li J, Ji YY, An P, Zhang S, Li Z. Traditional herbal medicine: a review of potential of inhibitory hepatocellular carcinoma in basic research and clinical trial. Evid Based Complement Alternat Med 2013; 2013: 268963PubMedPubMedCentralGoogle Scholar
  6. 6.
    Sun Z, Liang ST, Zhai XF, Lang QB, Zhou QH, Yue XQ, He J, Xu J, Zhu Y, Ling CQ. A traditional Chinese herbal medicine compound preparation versus interventional therapy after resection of small hepatocellular carcinoma: 22-year follow-up. J Tradit Chin Med 2012; 32(2): 156–163CrossRefPubMedGoogle Scholar
  7. 7.
    Li M, Qiao C, Qin L, Zhang J, Ling C. Application of traditional Chinese medicine injection in treatment of primary liver cancer: a review. J Tradit Chin Med 2012; 32(3): 299–307CrossRefPubMedGoogle Scholar
  8. 8.
    Wang B, Tian HQ, Liang GW, Huang XQ, Chen XZ, Huang ZQ. Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer. Chin J Integr TraditWest Med (Zhongguo Zhong Xi Yi Jie He Za Zhi) 2009; 29(3): 257–260 (in Chinese)Google Scholar
  9. 9.
    Yang CB, Guo DH, Zhang M, Zuo JS, Xu KC. Clinical efficacy of advanced hepatocellular carcinoma TCM Differential Treatment. J South Med Univ (Nan Fang Yi Ke Da Xue Xue Bao) 2007; 27(8): 1229–1230 (in Chinese)Google Scholar
  10. 10.
    Cui YD. Clinical efficacy of primary hepatic carcinoma 39 cases of righting cancer treatment. Henan Tradit Chin Med (Henan Zhong Yi) 2013; 33: 58–59 (in Chinese)Google Scholar
  11. 11.
    Han GX, Zhang MJ, Leng XB. Clinical observation of primary hepatic carcinoma in combination therapy. Shanxi J Tradit Chin Med (Shanxi Zhong Yi) 2009; 25(5): 29–30 (in Chinese)Google Scholar
  12. 12.
    Tian JZ, Li H, Huang LP. Aidi injection combined with Chinese herbal compound in the treatment of 30 cases with advanced primary liver cancer. J Chin Oncol (Zhong Liu Xue Za Zhi) 2009; 15(1): 86–87 (in Chinese)Google Scholar
  13. 13.
    Lin YT. Efficacy of 80 cases of primary hepatic carcinoma with treament of Shuganjianpi and Jieduhuayu. Guide China Med (Zhongguo Yi Yao Zhi Nan) 2012; 10(33): 617–618 (in Chinese)Google Scholar
  14. 14.
    Liu JL, Wang XH, Guo XG, Zhang Q, Yin WH, Zhang J. Treatment of tumor suppressor righting combined with chemotherapy in 33 cases of advanced liver cancer. Tradit Chin Med Research (Zhong Yi Yao Yan Jiu) 2005; 18(4): 34–36 (in Chinese)Google Scholar
  15. 15.
    Chen NJ, Wu DH, Lai YQ, Chen YY. Clinical analysis Xiaoaiping combined with chemotherapy in advanced liver cancer. Guangming J Chin Med (Guang Ming Zhong Yi) 2009; 24(6): 1111–1112 (in Chinese)Google Scholar
  16. 16.
    Zhou XB. Clinical observation of Cinobufacini injection used to treat primary liver cancer in 58 cases. China Pract Med (Zhongguo Shi Yong Yi Yao) 2010; 5(23): 6–7 (in Chinese)Google Scholar
  17. 17.
    Bai GD, Wu J. Kang’ai injection combined with CyberKnife program 25 cases of primary hepatic carcinoma treatment clinical observation. J New Chin Med (Xin Zhong Yi) 2012; 44(3): 81–83 (in Chinese)Google Scholar
  18. 18.
    Lin JJ, Jin CN, Zeng JX. Kang’ai injection combined with radiofrequency ablation treatment of primary hepatic carcinoma clinical observation. Guangming J Chin Med (Guang Ming Zhong Yi) 2009; 24(10): 1887–1889 (in Chinese)Google Scholar
  19. 19.
    Deng GZ, Wu XT, Li GY, Gui JC, Fang XD, Wu FD. Clinical observation of 56 cases of advanced liver cancer radiotherapy treatment shenling soup. J Sichuan Tradit Chin Med (Sichuan Zhong Yi) 2004; 22: 38–39 (in Chinese)Google Scholar
  20. 20.
    Pang J, Chen HT, Chen Y, Hao GY, Zhang MX, Fan R, Yang XZ, Li CQ. Whole-body knife radiotherapy combined with Chinese herbal drugs to treat large primary liver cancer. Chin J Oncol Prevent Treat (Zhongguo Ai Zheng Fang Zhi Za Zhi) 2012; 4(2): 158–162 (in Chinese)Google Scholar
  21. 21.
    Xiang FM. Clinical study of the treatment of hepatocellular carcinoma after interventional Bugan gas law. Dissertation. Nanjing: Nanjing University of Chinese Medicine, 2009 (in Chinese)Google Scholar
  22. 22.
    Chen LW, Du J, Tan JW, Huang ZW. Surgical treatment of primary hepatic carcinoma clinical research collaborative medicine. J Fujian Coll Tradit Chin Med (Fujian Zhong Yi Yao Da Xue Xue Bao) 2005; 15(2): 6–8 (in Chinese)Google Scholar
  23. 23.
    Chen HY, Yue XQ, Lang QB, Chen Z. Preliminary analysis on Chinese medicine therapeutic program for the liver cancer patients after operation. World J Integr TraditWest Med (Shi Jie Zhong Xi Yi Jie He Za Zhi) 2012; 7(6): 484–486 (in Chinese)Google Scholar
  24. 24.
    Chen LW, Lin J, Chen W, Zhang W. Effect of Chinese herbal medicine on patients with primary hepatic carcinoma in III stage during perioperational period: a report of 42 cases. Chin J Integr Tradit West Med (Zhongguo Zhong Xi Yi Jie He Za Zhi) 2005; 25(9): 832–834 (in Chinese)Google Scholar
  25. 25.
    Lin JH, Guo WJ. Clinical observation on Jianpi Liqi Recipe for treatment of 25 cases of distal metastasis in liver cancer. J Tradit Chin Med (Zhong Yi Za Zhi) 2005; 46(1): 26–28 (in Chinese)Google Scholar
  26. 26.
    Zheng N, Feng JP, Li M, Fang J, Wang YP. Chinese medicine combined with chemoembolization in the treatment of advanced hepatocellular carcinoma clinical observation. Hubei J Tradit Chin Med (Hubei Zhong Yi Za Zhi) 2010; 32(7): 12–14 (in Chinese)Google Scholar
  27. 27.
    Gu BY. Spleen Qi liver arterial infusion chemotherapy combined with traditional Chinese medicine in 32 cases of primary hepatic carcinoma. Chin Med Mod Distance Educat China (Zhongguo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu) 2011; 9(8): 62–63 (in Chinese)Google Scholar
  28. 28.
    Lin J. Clinical Fuzhengjiedu square hepatic arterial chemoembolization treatment of primary hepatic carcinoma. Hubei J Tradit Chin Med (Hubei Zhong Yi Za Zhi) 2008; 30(2): 30–31 (in Chinese)Google Scholar
  29. 29.
    Zhang NH, Chen GF, Shi QH, Yang W, Gao HL, Wu RT. Clinical observation of transcatheter hepatic arterial chemoembolization combined with Chinese herbal medicine in treating primary liver cancer. J New Chin Med (Xin Zhong Yi) 2012; 44(2): 72–75 (in Chinese)Google Scholar
  30. 30.
    Zeng PH, Gao WH, Jiang YL. 37 cases of summary in Yiqi Huayu Decoction combined with chemoembolization detoxification treatment of advanced hepatocellular carcinoma. Hunan J Tradit Chin Med (Hunan Zhong Yi Za Zhi) 2011; 27(6): 19–20 (in Chinese)Google Scholar
  31. 31.
    Di RQ, Zhai HY. Clinical observation of Chinese medicine combined with transcatheter arterial chemoembolization in treating 32 cases of advanced primary hepatic carcinoma. Shanghai J Tradit Chin Med (Shanghai Zhong Yi Yao Za Zhi) 2010;44(11):48–51 (in Chinese)Google Scholar
  32. 32.
    Lu Y, Liang D, Guo HY, Chen SQ, Zhao JX, Shao M. Therapeutic observation of primary hepatic carcinoma treated with Jianpi Jiedu Formula combined with TACE. World J Integr TraditWest Med (Shi Jie Zhong Xi Yi Jie He Za Zhi) 2011; 6(3): 244–246 (in Chinese)Google Scholar
  33. 33.
    Chi HC, Hu FS, Han D, Zhang Q. The effectiveness of liversoothing and spleen-strengthening traditional Chinese medicine combined with intra-arterial infusion of chemical medicine for advanced primary hepatocellular cancer patients. Chin J Inf Tradit Chin Med (Zhongguo Zhong Yi Yao Xin Xi Za Zhi) 2010; 17(6): 16–18 (in Chinese)Google Scholar
  34. 34.
    Li YH, Liang H, Zhang CH. Clinical medicine combined with transcatheter arterial chemoembolization treatment of primary hepatic carcinoma. J Nanjing Med Univ (Nanjing Yi Ke Da Xue Xue Bao) 2011; 31(5): 742–745 (in Chinese)Google Scholar
  35. 35.
    Zhang HT, Fang CT, Huang ZY, Wang G. Chinese medicine combined with interventional therapy for 31 cases of primary hepatic carcinoma. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2008; 18(3): 178–180 (in Chinese)Google Scholar
  36. 36.
    Yang ZJ, Deng ZM, Liu JB, Huang CJ. Influence on the life quality and immune function of liver cancer patients treated with Chinese medicine combined with Western medicine. Acta Chin Med (Zhong Yi Xue Bao) 2011; 26(8): 907–909 (in Chinese)Google Scholar
  37. 37.
    Yang J. Clinical observation of 40 cases of advanced liver cancer Aidi injection therapy. Proc Clin Med (Lin Chuang Yi Yao Shi Jian) 2008; 17(8): 683–684 (in Chinese)Google Scholar
  38. 38.
    Zhang H, Liu XF, Zhao ZH, Li CY, Li FY, Shi J. Clinical studies with interventional therapy Shuganjianpi medicine treatment of advanced liver cancer. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2009; 19(1): 16–18 (in Chinese)Google Scholar
  39. 39.
    Ling ZQ. Integrative treatment of liver cancer. Jilin Med (Jilin Yi Xue) 2010; 31(15): 2284 (in Chinese)Google Scholar
  40. 40.
    Rong Z, Mo CM, Huang Y, Hu ZB, Bai GD, He SY. Dujieqing oral liquid combined hepatic arterial chemotherapy embolism (TACE) in treatment of advanced primary liver cancer. J Liaoning Univ Tradit Chin Med (Liaoning Zhong Yi Yao Da Xue Xue Bao) 2013; 15(12): 18–20 (in Chinese)Google Scholar
  41. 41.
    Wang QS, Mao JH, Zhang NH, Chen GF, Tian Y, Ye ZZ. Transcatheter hepatic arterial chemoembolization combined with Chinese herbal medicine for intermediate and advanced liver cancer: clinical observation and life quality evaluation of 83 cases. J Nanchang Univ Med Sci (Nanchang Da Xue Xue Bao Yi Xue Ban) 2012; 52(11): 28–31 (in Chinese)Google Scholar
  42. 42.
    Tang JW, Pei JW, Tian TD, Yang D. Shugan Jieduhuoxue decoction and Western treatment of advanced hepatocellular carcinoma 31 cases. Tradit Chin Med Res (Zhong Yi Yan Jiu) 2014; 27(7): 26–28 (in Chinese)Google Scholar
  43. 43.
    Zhang H. Yiqihuoxue co-dimensional conformal radiotherapy in the treatment of primary hepatic carcinoma clinical analysis. Acta Chin Med Pharmacol (Zhong Yi Yao Xue Bao) 2014; 42(5): 125–128 (in Chinese)Google Scholar
  44. 44.
    Tan YF. 68 cases of advanced primary hepatic carcinoma treated with integrated traditional Chinese and Western medicine treatment. Med Aesthetics Beauty (Yi Xue Mei Xue Mei Rong) 2014; 5(4): 627–628 (in Chinese)Google Scholar
  45. 45.
    Shang HY, Guo F, Zhang WT. Clinical observation of TACE combined with Chinese herbal decoction in the treatment of hepatocarcinoma. Nei Mongol J Tradit Chin Med (Nei Meng Gu Zhong Yi Yao) 2014; (23): 36–38 (in Chinese)Google Scholar
  46. 46.
    Qiao XT, Wang KQ, Dai YH, Wang YG, Gao J, Wang M. Clinical observation of the treatment of primary hepatic carcinoma with the combination of Xiao Chai Hu Decoction and hepatic arterial chemoembolization. Shaanxi J Tradit Chin Med (Shaanxi Zhong Yi) 2014; 35(7): 835–836 (in Chinese)Google Scholar
  47. 47.
    Li W. Efficacy of supplementing qi and activating blood and promoting blood circulation on the treatment of advanced primary hepatic carcinoma. Shaanxi J Tradit Chin Med (Shaanxi Zhong Yi) 2014; 35(8): 968–970 (in Chinese)Google Scholar
  48. 48.
    Qin H. Clinical treatment of 80 cases of primary hepatic carcinoma treated with integrated Chinese and Western medicine. Mod Women: Front Med (Xian Dai Fu Nv: Yi Xue Qian Yan) 2014; 4 (10): 402 (in Chinese)Google Scholar
  49. 49.
    Tang LL. Clinical study of 30 cases of advanced primary hepatic carcinoma treated with integrated traditional Chinese and Western medicine. China Health Care & Nutrition (Zhongguo Bao Jian Ying Yang) 2014; 24(5 ): 2913–2914 (in Chinese)Google Scholar
  50. 50.
    Wang YM. Observation of the clinical curative effect of combination of Chinese traditional and western medicine in the treatment of primary liver cancer in 60 cases. Chin Commun Doct (Zhongguo She Qu Yi Shi) 2014; (35 ): 116–117 (in Chinese)Google Scholar
  51. 51.
    Wang Q, Long J. Clinical observation of traditional Chinese medicine combined with hepatic artery embolization in treatment of hepatocellular carcinoma. J Hubei Univ Chin Med (Hubei Zhong Yi Yao Da Xue Xue Bao) 2014; 16(3): 73–74 (in Chinese)Google Scholar
  52. 52.
    Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011Google Scholar
  53. 53.
    Deng TT. Diagnostics of traditional Chinese medicine. Shanghai: Shanghai Scientific and Technical Publishers, 1984:11 (in Chinese)Google Scholar
  54. 54.
    Chen Y, Xiong X, Wang C, Wang C, Zhang Y, Zhang X, Gao Y, Xing Y, Li J, Wang J, Liu X, Xing Y. The effects of wenxin keli on left ventricular ejection fraction and brain natriuretic Peptide in patients with heart failure: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2014;2014:242589PubMedPubMedCentralGoogle Scholar
  55. 55.
    Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res 2009; 28: 112CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Yanju B, Yang L, Hua B, Hou W, Shi Z, Li W, Li C, Chen C, Liu R, Qin Y, Lv W. A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain. Support Care Cancer 2014; 22(3): 825–836CrossRefPubMedGoogle Scholar
  57. 57.
    Meng MB, Cui YL, Guang YS. Traditional Chinese medicine plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Chin J Evid-Based Med (Zhongguo Xun Zheng Yi Xue Za Zhi) 2008; 8(1): 21–31 (in Chinese)Google Scholar
  58. 58.
    Yang F. Cooperation of Chinese and Western medicine treatment primary liver cancer’s systems assessment. Dissertation. Changsha: Hunan University of Traditional Chinese Medicine, 2010 (in Chinese)Google Scholar
  59. 59.
    Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7(3):e1000251CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013; 309(8): 814–822CrossRefPubMedGoogle Scholar
  61. 61.
    Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G. Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 2012; 140(3): 550–554CrossRefPubMedGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Hubei University of Chinese MedicineWuhanChina
  2. 2.Hepatopathy Institute, Affiliated Hospital of Hubei University of Chinese Medicine (Chinese Medicine Hospital in Hubei Province)WuhanChina

Personalised recommendations